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1. Introduction
Glioblastoma represents the most common primary brain tumor in adults. Despite improve‐
ments of multimodal therapy, the prognosis of this disease remains unfavorable. Thus, great
efforts have been made to identify therapeutic agents directed against those specific molecular
targets whose presence was shown to be associated with worse clinical outcomes. The
epidermal growth factor receptor (HER1/EGFR) has been identified as one such target, and
different compounds were developed to inhibit HER1/EGFR and/or its mutant form, EGFRvIII.
However, clinical trials did not confirm the initial enthusiasm conveyed by promising results
from experimental studies. Therefore, a therapeutic approach directed at inhibiting solely
HER1/EGFR does not seem to translate into a clinical benefit. In this chapter we discuss the
current therapeutic situation in the setting of glioblastoma while putting the spotlight on
erlotinib, a HER1/EGFR-targeted small molecule tyrosine kinase inhibitor.
The epidermal growth factor receptor belongs to the HER family of receptors and consists of
an extracellular ligand-binding site, a transmembraneous part and an intracellular tyrosine
kinase (TK) domain (Wells, 1999). Docking of its ligands, e.g., epidermal growth factor (EGF)
or transforming growth factor-α (TGF-α), to the ligand-binding site activates the intrinsic TK.
Subsequently, autophosphorylation of specific tyrosine residues within the cytoplasmic
catalytic kinase domain of the receptor and initiation of cytoplasmic signaling cascades such
as the ras-raf-mitogen-activated protein kinase (MAPK) pathway or the phosphatidylinositol
3-kinase (PI3-K)/Akt pathway occur (Arteaga, 2003; Scagliotti et al., 2004). As a consequence,
diverse cellular functions such as proliferation or differentiation are regulated (Wells, 1999).
HER1/EGFR overexpression or ligand-independent activation was found in various epithelial
malignancies (Earp et al., 2003). The causative relationship between dysregulation of the
HER1/EGFR and neoplastic disorder is explained by the affection of downstream signal
transduction which results in impaired apoptosis and/or stimulation of proliferation, tumori‐
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genesis, angiogenesis and invasion (Halatsch et al., 2006). Dysregulated HER1/EGFR signaling
may be caused by different mechanisms such as gene amplification resulting in HER1/EGFR
overexpression as shown for 40-50% of glioblastoma (Salomon et al., 1995). Mutational changes
of the intrinsic receptor structure constitute another mechanism that may lead to pathologically
altered HER1/EGFR signaling. The so-called EGFRvIII accounts for approximately 60% of all
HER1/EGFR mutants and is characterized by a constitutive activation (Frederick et al., 2000;
Karpel-Massler et al., 2010). The expression of EGFRvIII was shown to confer cellular trans‐
formation and enhanced tumorigenicity (Nishikawa et al., 1994).
Despite recent improvements, the clinical efficacy of existing therapeutic modalities remains
disappointing. Hence, in light of accumulating evidence for HER1/EGFR-mediated promotion
of tumor growth and malignant transformation, substantial interest in the realization of HER1/
EGFR-targeted therapeutic strategies developed. Small molecule tyrosine kinase inhibitors
such as erlotinib (Tarceva®, Genentech Inc., San Francisco, CA, U.S.A.), a combined inhibitor
of both, HER1/EGFR and EGFRvIII, are the clinically most advanced HER1/EGFR-targeted
agents (Karpel-Massler et al., 2009). After promising results derived from experimental studies
using erlotinib in a single agent approach were not confirmed by clinical trials, hopes now are
set on the identification of other targeted agents enhancing the antineoplastic activity of
erlotinib in a multi-targeted approach.
2. Current standard of care for patients with glioblastoma
Glioblastoma is the most frequently encountered astrocytic brain tumor in adults and accounts
for more than 50% of all gliomas (Reardon, D.A. & Wen, 2006). The tumor rapidly infiltrates
normal surrounding brain tissue. Patients with glioblastoma typically encounter tumor
progression or recurrence, and median survival is only 14.6 months (Stupp et al., 2005).
Neurologically safe, maximal surgical tumor resection is generally considered the first
therapeutic measure for the treatment of newly diagnosed glioblastoma. However, localization
of the tumor in or near eloquent brain areas will impose considerable restrictions on the
radicality of the surgical procedure in order to avoid severe postoperative neurological deficits.
Radiotherapy in combination with concomitant and adjuvant chemotherapy with temozolo‐
mide (Temodar®/Temodal®, Schering Corporation, Kenilworth, NJ, U.S.A.) is a viable postop‐
erative treatment option. Whole brain irradiation (50-60 Gy) was shown by several randomized
studies to increase survival by 14-36 weeks (Walker et al., 1980). While the chemotherapeutics
that were initially used for the adjuvant treatment of glioblastoma were only of minor benefit,
a randomized controlled trial in patients with newly diagnosed glioblastoma showed that
administration of temozolomide concomitantly with and subsequently to radiation therapy
significantly increased two-year survival from 10.4% to 26.5% and median survival from 12.1
to 14.6 months when compared to adjuvant radiation therapy alone (Stupp et al., 2005). With
this study, a new therapeutic standard was established. Nevertheless, a progression-free
survival and overall survival of only 6.9 and 14.6 months, respectively, strongly emphasize
that further improvement of glioblastoma therapy is urgently needed.
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Currently, a standard of care for the treatment of recurrent glioblastoma does not exist. In
general, repeated gross tumor resection should be attempted. However, this strategy might
not always be appropriate, especially when considering the fact that progressive tumor
invasion may significantly increase the risk of provoking neurological deficits. Chemothera‐
peutics that were especially used before the temozolomide era upon tumor relapse include
nitrosoureas such as carmustine (BCNU) or lomustine (CCNU) and alkylating agents such as
procarbazine. However, the antineoplastic activity of these agents in clinical trials was shown
to be rather modest (Rodriguez et al., 1989; Newton et al., 1990; Brandes et al., 2004). Irinotecan
(Camptosar®, Pfizer Pharmaceuticals, New York, NY, U.S.A.), an inhibitor of topoisomerase I
(Raymond et al., 2003; Reardon, DA et al., 2005), or bevacizumab (Avastin®, Genentech Inc.,
San Francisco, CA, U.S.A.), a humanized monoclonal antibody targeted to vascular endothelial
growth factor (VEGF), represent two compounds that have been introduced more recently for
the treatment of recurrent glioblastoma and that showed anti-glioblastoma activity (Stark-
Vance, 2005).
3. Why interfering with HER1/EGFR or EGFRvIII-mediated signaling?
Given the poor therapeutic efficacy of current treatment measures for glioblastoma, the need
for different therapeutic strategies is evident. HER1/EGFR is the most frequently amplified
gene in glioblastoma, and its overexpression was found in more than half of these tumors
which renders HER1/EGFR an outstanding therapeutic target (Salomon et al., 1995). Experi‐
mental studies show that HER1/EGFR stimulates tumor growth, invasion and migration
(Lund-Johansen et al., 1990). In addition, data from clinical studies suggest that HER1/EGFR
amplification is related to decreased overall survival and worse prognosis in patients with
glioblastoma (Lund-Johansen et al., 1990; Shinojima et al., 2003).
EGFRvIII represents the most common mutant form of HER1/EGFR and is characterized by
constitutive TK activity independent of ligand-binding (Batra et al., 1995; Frederick et al.,
2000). Analysis of the expression of HER1/EGFR and EGFRvIII in bioptic glioblastoma
specimens suggests concurrent overexpression of both EGFRvIII and HER1/EGFR in most of
the tumors (Biernat et al., 2004). Moreover, in an experimental study using a murine model of
human glioma xenografts, EGFRvIII expression was found to be related to increased prolifer‐
ation, inhibition of apoptosis, and tumor formation (Nishikawa et al., 1994; Nagane et al.,
1996). Other studies showed similar results and identified activation of the MAPK/ERK1/2 and
PI3-K/Akt pathways as driving forces of cellular proliferation and tumor progression
(Moscatello et al., 1998; Klingler-Hoffmann et al., 2001; Klingler-Hoffmann et al., 2003). In
addition, in a murine orthotopic xenograft model of glioblastoma, administration of a mono‐
clonal antibody targeting EGFRvIII (mAb 806) was shown to cause a significant decrease of
tumor growth, increase of apoptosis and prolongation of survival (Mishima et al., 2001).
The tumor-specific properties of EGFRvIII have also lead to the development of EGFRvIII-
targeted vaccines in order to provoke an immunologic response against EGFRvIII-bearing
glioblastoma cells. Potential antitumor efficacy of EGFRvIII-targeted vaccines had been shown
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by experimental studies. Immunization of mice with transfected allogenic 300.19/EGFRvIII
cells was reported to induce a major histocompatibility complex class I-restricted response
against EGFRvIII-bearing syngeneic B16-F10 melanoma or 560 astrocytoma cells that were
implanted intracranially (Ashley et al., 1997). In addition, vaccinated animals were shown to
have a significantly longer median survival upon intracranial tumor challenge when compared
to controls. Similar findings were reported for mice that were vaccinated with PEP-3-KLH
(rindopepimut, CDX-110, Celldex Therapeutics, Needham, MA, U.S.A.), a conjugate of a
peptide comprising the tumor-specific mutated segment of EGFRvIII (PEP-3) and keyhole
limpet hemocyanin (KLH) (Heimberger et al., 2003). In this study, C3H mice received vacci‐
nation with 100 µg of PEP-3-KLH 8, 6 and 2 weeks prior to intracerebral administration of
K1735 murine melanoma cells that were transfected with a murine homologue of the human
EGFRvIII, and additional vaccination 4 days after intracranial implantation of the tumor cells.
A more than 173% longer survival time was shown for mice vaccinated with PEP-3-KLH when
compared to mice receiving only KLH. Moreover, mice with already established intracranial
tumors that were treated with a single dose of the PEP-3-KLH vaccine 4 days after adminis‐
tration of the transfected K1735 cells had a 26% increase of median survival. Based on these
promising preclinical data, several clinical trials were conducted. In two phase II trials,
vaccination with PEP-3-KLH was examined in patients with EGFRvIII-expressing newly
diagnosed glioblastoma. In the ACTIVATE trial, 18 patients underwent gross-total tumor
resection prior to radiotherapy and concurrent chemotherapy with temozolomide followed
by vaccination with PEP-3-KLH bi-weekly for 3 doses and continued monthly until progres‐
sion (Sampson et al., 2010). The data were compared to a matched historical control group
(n=17). The median progression-free survival and overall survival were 14.2 months and 26
months, respectively, versus 6.3 months and 15 months, respectively, in the control group.
Notably, the patients who developed an EGFRvIII-specific antibody response had an overall
survival of 47.7 months (n=6) compared to an overall survival of 22.2 months in patients lacking
a specific antibody response (n=8). In the ACT II trial, 22 patients who met the same inclusion
criteria as for the ACTIVATE trial received the same therapeutic regimen except for an
additional treatment with temozolomide either at a dose of 200 mg/m2 for 5 days of a 28-day
cycle or at a dose of 100 mg/m2 for 21 days of a 28-day cycle in conjunction with the vaccination
therapy (Heimberger et al., 2009). Combination therapy of PEP-3-KLH and temozolomide was
well tolerated, and a favorable median overall survival of 20.5 months was reported. An
additional phase II study (ACT III) was conducted by Celldex Therapeutics. Sixty-five patients
with newly diagnosed EGFRvIII-positive glioblastoma were enrolled in this single-arm
multicenter study which was initially planned as a phase IIb/III randomized two-arm trial but
had to be transformed into a single-arm design due to withdrawal of consent to participate in
this study by 14 of the 16 patients that were randomized to the control group. In this study, a
median overall survival of 21.8 months was reported which encouraged Celldex to launch two
more studies: ACT IV, a randomized controlled phase III study in patients with newly
diagnosed EGFRvIII-positive glioblastoma and ReACT, a phase II study in patients with
EGFRvIII-positive recurrent glioblastoma. The final results of these studies are pending.
However, what needs to be taken into account is the fact that only a part of the glioblastomas
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express EGFRvIII. For this subset of patients, however, vaccination with PEP-3-KLH might
confer a significant clinical benefit.
4. Erlotinib for the treatment of glioblastoma
HER1/EGFR TK inhibitors such as erlotinib compete with adenosine triposphate and reversi‐
bly bind to the intracellular catalytic TK domain of HER1/EGFR or EGFRvIII thus inhibiting
autophosphorylation of the receptor as well as further downstream signaling (Halatsch et al.,
2006). In preclinical studies, erlotinib was shown to exert a variety of relevant antineoplastic
effects in the setting of glioblastoma. Lal et al. showed that exposure of transformed D54-MG
glioblastoma cells (D54-EGFRvIII) to 20 µM of erlotinib resulted in significant downregulation
of certain genes encoding pro-invasive proteins and in significant inhibition of the invasiveness
of D54-EGFRvIII cells (Lal et al., 2002). In a different study, erlotinib was shown to significantly
reduce cellular viability of six human glioblastoma-derived tumor-initiating cell lines when
given at a concentration of 5 µM (Griffero et al., 2003). This effect was shown to be in con‐
cordance with decreased EGF-induced phosphorylation of HER1/EGFR and subsequent
inhibition of the MAPK signaling pathway by reduced phosphorylation of ERK1/2. Moreover,
Halatsch et al. showed that the extent of erlotinib-mediated inhibition of anchorage-independ‐
ent growth of glioblastoma-derived cell lines correlates inversely with the cellular capability
to induce HER1/EGFR mRNA, emphasizing the important role of HER1/EGFR in the patho‐
genesis of glioblastoma (Halatsch et al., 2004).
Based on the positive findings reported by preclinical studies, much hope was set on the clinical
application of erlotinib in glioblastoma patients. To date, several published studies have
examined the effects of erlotinib on patients with recurrent or newly diagnosed glioblastoma.
In phase I trials, erlotinib exhibited a reasonable safety profile and was generally well tolerated
(Krishnan et al., 2006; Prados et al., 2006). In addition, EIAEDs were shown to accelerate drug
metabolism of erlotinib which requires dose modification of erlotinib or a change in the
antiepileptic drug regimen (Stupp et al., 2006). In terms of clinical efficacy, Raizer et al.
examined the effects of erlotinib applied at a dose of 150 mg/d on 42 patients with recurrent
glioblastoma and 43 patients with non-progressive glioblastoma following radiotherapy in a
phase II trial (Raizer et al., 2010). For the patients with recurrent glioblastoma, median overall
survival was reported as 6 months and median progression-free survival as only 2 months.
Median overall survival and the 12-month overall survival were reported as 14 months and
57%, respectively, for the patients with non-progressive glioblastoma after radiotherapy. Thus,
this study did not show a significant improvement of the clinical outcome attributable to the
treatment with erlotinib in patients with recurrent glioblastoma or non-progressive glioblas‐
toma after radiotherapy. However, Yung et al. showed that median overall survival and 6-
month progression-free survival of 48 patients with recurrent glioblastoma who were treated
with erlotinib reached or exceeded historical values for patients receiving chemotherapy for
recurrent glioblastoma (Yung et al., 2010). Notably, this study was discontinued due to an
insufficient number of responses after a planned interim analysis, and a control group was not
included. Van den Bent et al. showed in a randomized controlled phase II trial that only 11.4%
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of 54 patients with recurrent glioblastoma who were treated with erlotinib remained free of
progression after 6 months compared to 24.1% of patients in the control group who received
either temozolomide or BCNU (van den Bent et al., 2009). Moreover, median overall survival
was shown to be similar across the treatment groups (7.7 months for the erlotinib group versus
7.3 months for the temozolomide/BCNU group).
Thus, taking erlotinib to clinical application in a monotherapeutic approach has so far fallen
short of expectations. As a logical consequence, the question rose if erlotinib might provide a
therapeutic benefit when combined with conventional radiochemotherapy. As outlined in
detail in the following, the addition of erlotinib to a combined regimen of temozolomide and
radiotherapy did not meet enthusiastic expectations and even raised the suspicion of inducing
serious toxic side effects. In a phase I/II trial, Brown et al. studied the clinical efficacy of a
combined treatment with erlotinib, temozolomide and radiotherapy in 89 patients with newly
diagnosed glioblastoma (Brown et al., 2008). Erlotinib was administered at a dose of 150
mg/d starting 1 week prior to fractionated radiotherapy (60 Gy) and chemotherapy with
temozolomide at a dose of 75 mg/m2/d. After radiotherapy, treatment with erlotinib was
continued and accompanied by up to six cycles of temozolomide at a dose of 200 mg/m2/d for
5 days every 4 weeks. Median overall survival was reported as 15.7 months, and comparison
to the “radiotherapy plus temozolomide arm” from the European Organisation for Research
and Treatment of Cancer 26981/22981-National Cancer Institute of Canada trial revealed no
significant difference (Mirimanoff et al., 2006). In contrast, Prados et al. showed in another
phase II trial which included 65 patients with newly diagnosed glioblastoma or gliosarcoma
receiving treatment with erlotinib and fractionated radiotherapy with concomitant and
adjuvant temozolomide a marked improvement of median progression-free and overall
survival (8.2 months and 19.3 months, respectively) when compared to a combined historical
control (Prados et al., 2009). Rather disturbing results were reported from a phase II study
published by Peereboom et al. (Peereboom et al., 2010). Twenty-seven patients with newly
diagnosed glioblastoma were treated with a maximum dose of 150 mg/d erlotinib and
radiotherapy (60 Gy in 30 fractions) with concurrent (75 mg/m2/d for 42 days) and subsequent
(12 four-week cycles comprising each 5 days of 150-200 mg/m2/d) temozolomide. This trial was
terminated preterm because of unacceptable toxicity and lack of efficacy. Median progression-
free and overall survival were 2.8 months and 8.6 months, respectively. Twenty-two patients
(67%) had progressive disease, and 4 patients (15%) had an adverse event. Three deaths
occurred that were reported to be treatment-related. One patient died of pneumocystis carinii
pneumonia despite treatment with pentamidine. Similarly, Brown et al. reported two cases of
fatal pneumocystis carinii pneumonia (Brown et al., 2008). Again high expectations were
disappointed.
5. Future perspectives
None of the therapeutic strategies evaluated so far involving erlotinib either alone or in
combination with conventional adjuvant therapies represent a major success for the treatment
of glioblastoma. Therefore, changing the general strategy towards a combined approach with
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HER1/EGFR TK inhibitors and other targeted agents might provide a more pronounced
clinical benefit for patients suffering from this disease.
In experimental studies, favorable effects were observed for the inhibition of downstream key
regulators such as mammalian target of rapamycin (mTOR) and PI3-K in addition to the
treatment with HER1/EGFR TK inhibitors. For example, phosphatase and tensin homolog
deleted on chromosome 10 (PTEN)-deficient U87MG and SF295 glioblastoma cells that were
subjected to a combined treatment with erlotinib and rapamycin, an mTOR inhibitor, showed
significantly increased antiproliferative effects when compared to cells receiving erlotinib
alone (reduction of proliferation by 38% versus 14%, respectively, in PTEN-deficient SF295
cells) (Wang et al., 2006). Another experimental study showed similar findings (Fan et al.,
2007). In this study, additional inhibition of PI3-K using a dual mTOR/PI3-K inhibitor (PI-103)
resulted in even more pronounced antiproliferative efficacy in PTEN-mutant glioma cells
when combined with erlotinib in comparison to erlotinib combined with either mTOR or PI3-
K inhibition. In a clinical pilot study including 22 patients with recurrent glioblastoma, Doherty
et al. showed that patients treated with erlotinib or gefitinib in combination with sirolimus
(rapamycine, Rapamune®, Wyeth Pharmaceuticals Inc., Ayerst, PA, U.S.A.) had a 6-month
progression-free survival of 25% (Doherty et al., 2006). In addition, 32 patients with recurrent
glioblastoma were treated with 150 mg/d (450 mg/d when on EIAEDs) of erlotinib and 5
mg/d (10 mg/d when on EIAEDs) of sirolimus in a phase II clinical trial (Reardon, DA et al.,
2010). In this study, however, antitumor activity was negligible with no complete or partial
responses and a median progression-free survival and a median overall survival of 6.9 weeks
and 33.8 weeks, respectively.
Carboplatin was shown to have some antineoplastic activity in patients with recurrent
glioblastoma and anaplastic astrocytoma (Prados et al., 1996). De Groot et al. examined the
therapeutic efficacy of a combined regimen of the cytotoxic agent carboplatin and erlotinib in
recurrent glioblastoma (de Groot et al., 2008). In this phase II study, 43 patients were treated
with erlotinib at a dose of 150 mg/d that was escalated up to 200 mg/d as tolerated in combi‐
nation with carboplatin administered once every 4 weeks at doses modified according to renal
function. While this regimen was well tolerated, antineoplastic activity was modest. Median
progression-free survival and overall survival were 9 weeks and 30 weeks, respectively, and
only one partial response was achieved.
Tumor angiogenesis has been shown to be a crucial process for the growth and metastasis of
solid tumors (Heath & Bicknell, 2009). The combined treatment with bevacizumab and HER1/
EGFR-targeted agents has been evaluated by two recent phase II studies in the setting of
recurrent high-grade glioma. Forty-three patients with recurrent glioblastoma were treated
with 10 mg/kg bevacizumab, 125 or 340 mg/m2 irinotecan (dose depending on EIAED come‐
dication), and cetuximab, a monoclonal antibody targeted at HER1/EGFR (loading dose of 400
mg/m2 followed by weekly administration of 250 mg/m2) (Hasselbalch et al., 2010). Two
complete responses (5%) and 9 partial responses (21%) were observed. Stable disease was
achieved in 17 patients (40%). Median overall survival and progression-free survival were 30
weeks and 16 weeks, respectively. In the second phase II trial, twenty-five patients with
recurrent primary glioblastoma were treated with 10 mg/kg bevacizumab every 2 weeks and
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concomitantly with 200 or 500 mg/d erlotinib (dose depending on EIAED comedication)
(Sathornsumetee et al., 2010). Median overall survival and 6-month progression-free survival
were reported as 42 weeks and 28%, respectively. Moreover, radiographic response was
observed for 48% of the glioblastoma patients. Unfortunately, appropriate control groups were
not included in this study. However, comparison to historical data of patients treated with
bevacizumab only showed a similar progression-free survival and radiographic response.
Thus, additional inhibition of HER1/EGFR does not appear to greatly increase the clinical
efficacy when combined with bevacizumab in recurrent glioblastoma.
Overall, while promising results were reported by some early phase clinical trials evaluating
the therapeutic efficacy of a combined treatment with HER1/EGFR TK inhibitors and other
agents, further studies with a randomized controlled design and a larger patient population
will be needed to make a final judgment.
Considering the fact that a multitude of different converging and diverging signaling path‐
ways are involved in the maintenance and progression of glioblastoma, the failure of targeting
of a single molecular determinant such as HER1/EGFR does not come as a surprise. Moreover,
limiting the focus on therapeutic strategies targeted at already known oncogenic signaling
pathways might impede further progress. Therefore, the search for novel targets is crucial in
order to allow for a more efficient treatment of glioblastoma. A bioinformatic approach might
help to identify molecules that are potentially relevant as tumor-driving forces. Halatsch et
al. identified a panel of genes overexpressed in glioblastoma cells with an erlotinib-resistant
phenotype by RNA microarray analysis of which some have been confirmed as promising co-
targets in vitro (Halatsch et al., 2009; Karpel-Massler et al., 2013). Hopefully, in the future, broad
molecular tumor screening will lead to the identification of individual molecular signatures
amenable to successful multitargeting. Since these molecular signatures are likely to change
during therapy, repeated therapeutic adjustments will be necessary based on updated
molecular characteristics of the tumor (Cloughesy & Mischel, 2011). This kind of dynamic
personalized therapy of glioblastoma will likely involve HER1/EGFR-targeted therapeutics
such as erlotinib at one point.
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